Pokrzywka przewlekła u chorej na ciężką astmę atopową – podwójna korzyść z leczenia omalizumabem

Publication date: Available online 3 November 2016
Source:Alergologia Polska - Polish Journal of Allergology
Author(s): Joanna Goździk-Spychalska, Małgorzata Rzymkowska, Halina Batura-Gabryel
Urticaria is one of the most common skin disorders. A characteristic feature of this disease is the sudden appearance and rapid regression (up to 24hours) of blisters, angioedema, or both of these simultaneously. Often, the above changes are accompanied by symptoms of itching and pain. Chronic urticaria, i.e. one that lasts for at least 6 weeks, is divided into spontaneous (CSU) and induced. CSU, because of its unpredictable nature, strongly reduces the quality of life, especially the patient's active professionally and socially. Below is a description of a 38-year-old female patient, with the profession of teacher diagnosed with atopic chronic severe asthma coexisting with CSU, which has been qualified for the program with omalizumab in 2013, i.e., one year before the registration of the drug in the latter diagnosis. Since the inclusion of the patient into the program in addition to the vast improvement in asthma control in spite of the withdrawal of systemic corticosteroids (sGCS) and the reduction of inhaled glucocorticosteroids (ICS), any episode of CSU is not repeated which is undoubtedly the added benefit of applied therapy.



http://ift.tt/2fjZj22